A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems)
Public ClinicalTrials.gov record NCT05915728. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Prospective Double-blind, Cross-over Phase 3 Study to Evaluate the Efficacy and Safety of 0.04 mmol Gd/kg Body Weight of Gadoquatrane for MRI in Adults With Known or Suspected Pathology of Any Body Region (Except CNS), Compared to 0.1 mmol Gd/kg Approved Macrocyclic Gadolinium-based Contrast Agents (GBCAs)
Study identification
- NCT ID
- NCT05915728
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Bayer
- Industry
- Enrollment
- 404 participants
Conditions and interventions
Interventions
- Gadobutrol Drug
- Gadoquatrane (BAY1747846) Drug
- Gadoterate meglumine Drug
- Gadoteridol Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 23, 2023
- Primary completion
- May 30, 2024
- Completion
- May 31, 2024
- Last update posted
- Dec 21, 2025
2023 – 2024
United States locations
- U.S. sites
- 9
- U.S. states
- 8
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UAB Hospital - Radiology | Birmingham | Alabama | 35233 | — |
| Halo Diagnostics - Indian Wells | Indian Wells | California | 92210 | — |
| UC Irvine Medical Center | Orange | California | 92868 | — |
| University of Connecticut Health Center | Farmington | Connecticut | 06032 | — |
| Biogenix Molecular, LLC | Miami | Florida | 33165 | — |
| University of Missouri Hospital and Clinic - Neuroradiology | Columbia | Missouri | 65212 | — |
| Duke University School of Medicine - Early Phase Research Unit - Neurology | Durham | North Carolina | 27710 | — |
| Pennsylvania State University College of Medicine | Hershey | Pennsylvania | 17033 | — |
| Houston Methodist Hospital - Cardiology | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 75 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05915728, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 21, 2025 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05915728 live on ClinicalTrials.gov.